SARS-CoV-2 VLP Vaccine Platform based on MVA Vector

The number of patients with SARS-CoV-2 pneumonia in the world has exceeded 10 million, and accelerating the development of vaccine products will become a key way to solve this global disaster. With mature and well-established vaccine development system, Creative Biolabs has several vaccine-related platforms, which can provide complete vaccine development and evaluation services to overcome COVID-19.

Urgent Need for SARS-CoV-2 Vaccine

To completely defeat SARS-CoV-2 and to be free from its long-term interference, we need not only special drugs but also more important thing - a vaccine! The research and development of the new coronavirus vaccine play a very important role in protecting people's health and safety. At present, a number of technical routes, including inactivated vaccines, mRNA vaccines, recombinant protein vaccines, viral vector vaccines, and DNA vaccines, are under development, and some vaccine varieties have entered the stage of animal experiments. Currently, the overall progress of vaccine research and development is satisfying, but there are still many uncertainties. Trying various strategies for vaccine research and development is still an avenue worth paying attention.

Feasibility of MVA to be a Vaccine Vector

MVA (modified vaccinia virus Ankara strain) is a highly attenuated vaccinia strain obtained by humans in the process of seeking vaccinia virus as a smallpox vaccine. After MVA infects a cell, the genome does not enter the nucleus, but relies on its promoter and transcription system in the cytoplasm to complete gene replication and expression. During the passaging process, MVA lost six major gene fragments. These parts can be used to insert foreign genes of more than 25kb, and the insertion of foreign genes does not affect the virus' ability to infect and express itself. As a smallpox vaccine strain, more than 120,000 people were immunized in the 1970s, including patients with abnormal immune functions, patients with allergies and skin diseases, chronic patients, infants, and young children. None of the people receiving MVA inoculation had serious adverse reactions. MVA has been well evaluated in animal models and human trials. In terms of the immune response caused, MVA is a highly attenuated non-replicating vaccinia virus strain, which is cleared 48 hours after infection with mammals, but it can elicit strong and durable antiviral immune responses.

VLP (MVA) Vector Vaccine Platform at Creative Biolabs

Creative Biolabs has developed an efficient VLP (MVA) platform based on the MVA vector and combined with VLP expression technology. The vaccine prepared through this platform can package highly immunogenic virus-like particles (VLP) with target protein in the vaccinated individuals, and also has the safety and immunity persistence characteristics of MVA. We have used our VLP (MVA) vaccine platform to design several candidate vaccines using the SARS-CoV-2 gene sequence. They have undergone purification and identification steps and can be used for immune evaluation in animal models.

Highlight Advantages of VLP (MVA) Platform

• Safety of MVA
• Durable humoral and cellular immune responses
• Sterile immunity by single-dose immunization
• Little vector immunity
• Self-adjuvanting
• Thermostable

If you are interested in our service, please feel free to contact us.

For Research Use Only. We do not provide direct services or products for patients.